Cargando…

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study

Most patients with asthma can control their symptoms with a basic standard of medical care and with maintenance and rescue medication. However, between 5% and 10% of asthmatics worldwide do not achieve control of their symptoms and have recurrent exacerbations and respiratory difficulties. The objec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojo-Tolosa, Susana, González-Gutiérrez, María Victoria, Sánchez-Martínez, José Antonio, Jiménez-Gálvez, Gonzalo, Pineda-Lancheros, Laura Elena, Gálvez-Navas, José María, Jiménez-Morales, Alberto, Pérez-Ramírez, Cristina, Morales-García, Concepción
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962091/ https://www.ncbi.nlm.nih.gov/pubmed/36839845 http://dx.doi.org/10.3390/pharmaceutics15020523

Ejemplares similares

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease
por: González Rojo, Paula, et al.
Publicado: (2022)

Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer
por: Pineda Lancheros, Laura Elena, et al.
Publicado: (2022)

Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway and Their Relationship with High Blood Pressure Risk
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 Genes as Biomarkers of Survival in Non-Small Cell Lung Cancer: A Systematic Review
por: Pineda-Lancheros, Laura Elena, et al.
Publicado: (2023)

Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway as Survival Biomarkers in Colorectal Cancer
por: Pérez-Durán, Carmen, et al.
Publicado: (2023)

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer
por: Pineda Lancheros, Laura Elena, et al.
Publicado: (2021)

Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics
por: Sintobin, Ina, et al.
Publicado: (2015)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic
por: Kirchnerová, Olga Růžičková, et al.
Publicado: (2018)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
por: Sztafińska, Anna, et al.
Publicado: (2021)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
por: Entrenas Costa, Luis Manuel, et al.
Publicado: (2019)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

The “real-world” effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study
por: Siracká, Simona, et al.
Publicado: (2022)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Ramírez-Tortosa, César L., et al.
Publicado: (2022)

Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
por: Membrive-Jiménez, Cristina, et al.
Publicado: (2023)

Loss of asthma control after cessation of omalizumab treatment: real life data
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f217fqbeqgv2uu43rfodfb4lcd